Takeda sees first-half sales and earnings decline

30 October 2025

Japan’s largest drugmaker Takeda (TYO: 4502) today announced earnings results for the first half of fiscal year 2025 (six months ended September 30, 2025) and updated its full-year outlook.

Takeda reported a 6.9% year-over-year decline in revenue for the first half, reaching 2,219.5 billion yen ($14.5 billion). The company has revised its full-year forecast for FY2025 due to currency fluctuations and charges related to its cell therapy platform.

Earnings per share was 70.45 yen compared to 117.11 yen. Core operating profit was 639.2 billion yen, down 11.2%. Core EPS was 279 yen compared to 310 yen.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK